KR900701749A - 치환 아세트아미드 유도체, 그의 제조법 및 이를 함유하는 항궤양제 - Google Patents

치환 아세트아미드 유도체, 그의 제조법 및 이를 함유하는 항궤양제

Info

Publication number
KR900701749A
KR900701749A KR1019900700443A KR900700443A KR900701749A KR 900701749 A KR900701749 A KR 900701749A KR 1019900700443 A KR1019900700443 A KR 1019900700443A KR 900700443 A KR900700443 A KR 900700443A KR 900701749 A KR900701749 A KR 900701749A
Authority
KR
South Korea
Prior art keywords
group
hydroxyethyl
general formula
integer
hydroxy
Prior art date
Application number
KR1019900700443A
Other languages
English (en)
Inventor
노 자끼 가쯔오 시
가쯔유끼 이시이
이쿠오 우에다
Original Assignee
이베 사치아끼
제리아 신야꾸 고오교 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이베 사치아끼, 제리아 신야꾸 고오교 가부시끼 가이샤 filed Critical 이베 사치아끼
Publication of KR900701749A publication Critical patent/KR900701749A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

내용 없음

Description

치환 아세트아미드 유도체, 그의 제조법 및 이를 함유하는 항궤양제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 다음 일반식(Ⅰ)
    [식중, Y는 피페리딘기, 1-피롤리디닐기 또는 3-히드록시-1-피롤리디닐기를 나타내고, Z는 다음(a)∼(e) (a)아미노기, (b)(식중, ℓ은 0내지 2의 정수, n은 1내지 3의 정수이며, R1은 히드록시기,1, 2-디히드록시에틸기, 1-히드록시에틸기, 2-페녹시-1-히드록시에틸기, 2-히드록시에톡시기, 저급알콕시카르보닐기, 2, 2-디메틸-1,3-디옥소란-4-일기 또는 저급아실옥시 메틸기를 나타낸다)로 표시되는 기, (c)(식중, R2는 아미노기, 저급알킬 아미노기, 디(2-히드록시에틸)아미노기, 저급알킬기 또는 저급알콕시기를 나타낸다)로 표시되는기, (d)(식중, R3및 R4는 수소원자 또는 저급알킬기를 나타낸다)로 표시되는 기,
    (식중, 1은 0내지 2의 정수, R5및 R6는 수소원자 또는 저급알킬기를 나타낸다)로 부터 선택된 기이다. 표시되는 치환 아세트아미드 유도체 및 그의 염.
  2. N-[3-[3-(피페리디노메틸)페녹시]프로필]-2-(2-히드록시에틸-1-티오)아세트아미드.
  3. 시클로텍스트린에 제1항 기체의 화합물을 포접시켜서 된 포접체.
  4. 일반식(Ⅱ)
    (식중, X는 할로겐원자, Y는 피페리디노기, 1-피롤리디닐기 또는 3-히드록시-1피롤리디닐기를 나타낸다]로 표시되는 아세트아미드 유도체와 일반식(Ⅲ)
    A-Za (Ⅲ)
    [식중, A는 수소원자, 칼륨원자 또는 나트륨원자를 나타내고, Za는 시아노기 또는 (b')-S-(CH2n)-R1(여기서, n은 1내지 3의 정수이며, R은 히드록시기, 1,2-디히드록시에틸기, 1-히드록시에틸기, 2-페녹시-1-히드록시에틸기, 2-히드록시에톡시기, 저급알콕시 카르보닐기, 2,2-디메틸-1,3-디옥소란-4-일 기 또는 저급아실옥시 메틸기를 나타낸다)로 표시되는 기이다]로 표시되는 화합물을 반응시킴을 특징으로 하는 일반식(Ⅰa)
    [식중, Y 및 Za는 전술한 바와 같다]로 표시되는 치환 아세트아미드 유도체의 제조법.
  5. 일반식(Ⅳ)
    [식중, Y는 피페리디노기, 1-피롤리디닐기 또는 3-히드록시-피롤리디닐기를 나타낸다]로 표시되는 아민 유도체와 일반식(V)
    B-Zb (Ⅴ)
    [식중, B는 저급알콕시 카르보닐메틸기, Zb는 다음(a)∼(e) (a)시아노기, (b)(식중, ℓ은 0내지 2의 정수, n은 1내지 3의 정수이며, R1a은 히드록시기,1, 2-디히드록시에틸기, 1-히드록시에틸기, 2-페녹시-1-히드록시에틸기, 2-히드록시 에톡시기 또는 2, 2-디메틸-1,3-디옥소란-4-일기를 나타낸다)로 표시되는 기, (c)(식중, R2a는 아미노기, 저급알콕시 아미노기, 디(2-히드록시에틸)아미노기 또는 저급알콕시기로 나타낸다)로 표시되는기, (d)(식중, R3및 R4는 수소원자 또는 저급알킬기를 나타낸다)로 표시되는 기.
    (식중, R5및 R6는 수소원자 또는 저급알킬기를 나타낸다)로 부터 선택된 기이다]로 표시되는 화합물을 반응시킴을 특징으로 하는 일반식(Ⅰb)
    [식중, Y 및 Zb는 전술한 바와 같다]로 표시되는 치환 아세트아미드 유도체의 제조법.
  6. 일반식(Ⅳ)
    [식중, Y는 피페리디노기, 1-피놀리디닐기 또는 3-히드록시-1-피놀리디닐기를 나타낸다]로 표시되는 아민유도체와 일반식(Ⅳ)
    [식중, n은 1내지 3의 정수를 나타낸다]로 표시되는 화합물을 반응시킴을 특징으로 하는 일반식(Ⅰc)
    [식중, Y는 전술한 바와 같다. n은 1내지 3의 정수를 나타낸다]로 표시되는 치환 아세트아미드 유도체의 제조법.
  7. 일반식(Ⅰe)
    [식중, Y는 피페리디노기, 1-피롤리디닐기 또는 3-히드록시-1-피롤리디닐기를 나타내며, R26는 저급알콕시기를 나타낸다]로 표시되는 아세트아미드 유도체와 일반식(Ⅶ)
    H-R2C(Ⅶ)
    [식중, R2C는 아미노기, 저급알킬 아미노기, 디(2-히드록시에틸)아미노기를 나타낸다]로 표시되는 화합물을 반응시킴을 특징으로 하는 일반식(Ⅰd)
    [식중, Y 및 R2C는 전술한 바와같다]로 표시되는 치환 아세트아미드 유도체의 제조법.
  8. 일반식(Ⅰg)
    [식중, Y는 피페리디노기, 1-피롤리디닐기 또는 3-히드록시-1-피롤리디닐기를 나타내고, Zc는 (b′)-S-(CH″2)-R1(식중, n은 1내지 3의 정수이며, R1은 히드록시기, 1,2-디히드록시에틸기, 1-히드록시에틸기, 2-페녹시-1-히드록시에틸기, 2-히드록시에톡시기, 저급알콕시 카르보닐기, 2,2-디메틸-1,3-디옥소란-4-일기 또는 저급아실옥시메틸기를 나타낸다)로 표시되는 기, 또는
    [식중, R5및 R6는 수소원자 또는 저급알킬기를 나타낸다)로 표시되는 기이다]로 표시되는 아세트아미드 유도체를 산화시킴을 특징으로 하는 일반식(Ⅰf)
    B식중, Y는 전술한 바와같다. Zd는[식중, q는 1 또는 2의 정수이며, n 및 R1은 전술한 바와같다]로 표시되는 기 또는
    [식중, q는 1또는 2의 정수이며, R5및 R6는 전술한 바와같다]로 표시되는 치환 아세트아미드 유도체의 제조법.
  9. 제1항 기재의 치환 아세트아미드 유도체 또는 그의 염 또는 이들과 시클로덱스트린과의 포접체를 유효성분으로 하는 항궤양제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700443A 1988-07-05 1989-07-04 치환 아세트아미드 유도체, 그의 제조법 및 이를 함유하는 항궤양제 KR900701749A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP16582288 1988-07-05
JP165822/88 1988-07-05
PCT/JP1989/000670 WO1990000544A1 (en) 1988-07-05 1989-07-04 Substituted acetamide derivatives, process for their preparation and antiulcer drug containing same

Publications (1)

Publication Number Publication Date
KR900701749A true KR900701749A (ko) 1990-12-04

Family

ID=15819658

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700443A KR900701749A (ko) 1988-07-05 1989-07-04 치환 아세트아미드 유도체, 그의 제조법 및 이를 함유하는 항궤양제

Country Status (4)

Country Link
US (1) US5192774A (ko)
EP (1) EP0404949A4 (ko)
KR (1) KR900701749A (ko)
WO (1) WO1990000544A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692948A (ja) * 1992-03-04 1994-04-05 Snow Brand Milk Prod Co Ltd 新規なアセタミド誘導体及びその用途
TW240222B (ko) 1992-03-23 1995-02-11 Sankyo Co
WO1994012473A1 (en) * 1992-11-20 1994-06-09 Kaken Pharmaceutical Co., Ltd. Acetamide derivative
KR100407720B1 (ko) * 2001-09-20 2003-12-01 경동제약 주식회사 Ｎ-[3-｛3-（1-피페리디닐메틸）페녹시｝프로필]아세톡시아세트아미드의 제조방법
US9598361B1 (en) 2016-04-12 2017-03-21 King Saud University Amino substituted acetamide derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837316A (en) * 1985-08-29 1989-06-06 Fujirebio Kabushiki Kaisha Alkylamide derivatives with H2 -receptor antagonistic and cytoprotective action
JPH0662551B2 (ja) * 1985-08-29 1994-08-17 富士レビオ株式会社 置換フエノキシプロピルアミド誘導体およびその製造法

Also Published As

Publication number Publication date
EP0404949A4 (en) 1991-07-17
WO1990000544A1 (en) 1990-01-25
EP0404949A1 (en) 1991-01-02
US5192774A (en) 1993-03-09

Similar Documents

Publication Publication Date Title
KR930004292A (ko) 카르보스티릴유도체 및 그것을 함유한 의약조성물
AU7316900A (en) Compounds for fluorescence labeling
KR880013888A (ko) 신규 디티오아세탈 화합물, 그의 제조방법 및 이 화합물로 되는 제약 조성물
KR850004463A (ko) 디히드로피리딘 유도체의 제조방법
KR840003636A (ko) 약리학적으로 활성인 피라졸로/4,3-c/피리딘 제조방법
KR840008001A (ko) 티아졸리딘 유도체의 제조방법
KR840006968A (ko) 1,4-디하이드로 피리딘의 제조방법
KR910002800A (ko) 4-아실록시퀴놀린 유도체와 이를 함유하는 살충 또는 살비조성물
KR950702976A (ko) 벤조피란 및 벤족사진 유도체[benzopyran and benzoxazine derivatives]
KR900701749A (ko) 치환 아세트아미드 유도체, 그의 제조법 및 이를 함유하는 항궤양제
SE8000920L (sv) 4-(naftylmetyl)piperidinderivat
KR900006347A (ko) 살균성 플루오로퀴놀로닐 세펨
KR860001819A (ko) 티아(옥사)디아졸 유도체의 제조방법
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR920009810A (ko) 나프토에산 유도체
KR870001203A (ko) 치환된 3-아미노-시드논이민의 제조 방법
DE3778714D1 (de) Indenothiazolderivate und verfahren zu ihrer herstellung.
KR960704877A (ko) 이미다졸리딘온 유도체, 이의 산부가염 및 노인성 치매 치료제 (Imidazolidinone derivative, acid-addition salt thereof, and remedy for senile dementia)
KR920000726A (ko) 퀴놀린카르복실산의 제조 방법
KR910011839A (ko) 이미다졸리딘 유도체, 그의 제조 방법 및 이를 함유하는 살충제
KR880011140A (ko) 벤조디옥솔 유도체
SE8005493L (sv) 4-(haftalenyloxi)piperidin-derivat
KR840001154A (ko) 1,2-디티올-3-일리덴 암모늄 유도체의 제조방법
KR860008172A (ko) 1,3,4-티아디아졸 유도체의 제조방법
KR850004458A (ko) 아제티디논의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application